SLC25A47P1: A Drug Target / Disease Biomarker (G105369316)

Target Name: SLC25A47P1

NCBI ID: G105369316

SLC25A47P1

Other Name(s): Solute carrier family 25 member 47 pseudogene 1 | solute carrier family 25 member 47 pseudogene 1

SLC25A47P1: A Drug Target / Disease Biomarker

SLC25A47P1 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the SLC25 family of transport proteins, which are involved in the transport of a variety of molecules across cell membranes. One of the unique aspects of SLC25A47P1 is its expression pattern, which is highly enriched in the brain and nervous system.

SLC25A47P1 has been identified as a potential drug target or biomarker for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Its expression has also been associated with various neurological injuries, such as stroke and trauma.

The SLC25A47P1 protein is expressed in the brain and nervous system, and its levels are higher in the brain than in other tissues. It is involved in the transport of various molecules across cell membranes, including neurotransmitters, which are involved in the transmission of signals within the nervous system.

One of the key functions of SLC25A47P1 is its role in the transporter of neurotransmitters, which is responsible for transporting these molecules from the cell body to the cell surface. This transporter is critical for the proper functioning of the nervous system, and is thought to be involved in the development and progression of various neurological disorders.

SLC25A47P1 has also been shown to be involved in the transport of other molecules that are involved in neurotransmission, including ions, peptides, and small molecules. These molecules play important roles in the regulation of various physiological processes in the brain and nervous system, and may be involved in the development and progression of neuropsychiatric disorders.

In addition to its role in neurotransmission, SLC25A47P1 is also involved in the regulation of various cellular processes that are important for brain function. This includes the regulation of ion channels, which are responsible for the flow of electrical signals through the cell membrane, as well as the regulation of protein synthesis and degradation.

SLC25A47P1 is also involved in the regulation of cellular signaling pathways that are important for brain development and plasticity. This includes the regulation of various signaling pathways that are involved in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

SLC25A47P1 has also been shown to be involved in the regulation of various cellular processes that are important for pain perception and neuroinflammation. This includes the regulation of pain signaling pathways, as well as the regulation of neuroinflammation, which is the inflammation that occurs in the brain as a result of injury or disease.

In conclusion, SLC25A47P1 is a protein that is involved in various cellular processes that are important for brain function and development. Its expression is highly enriched in the brain and nervous system, and it has been identified as a potential drug target or biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of SLC25A47P1 in the development and progression of these disorders.

Protein Name: Solute Carrier Family 25 Member 47 Pseudogene 1

The "SLC25A47P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A47P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets